

**FOR IMMEDIATE RELEASE**

**For Further Information**

**Fern Lazar, Lazar Partners**  
**(212) 867-1762**  
**flazar@lazarpartners.com**

**AESTHETICS AND PLASTIC SURGERY COMPANY SIENTRA INC.**  
**RAISES \$85 MILLION IN SERIES B FINANCING**

*- Company Acquires Assets of Silimed Inc: An Established Cosmetic and  
Reconstructive Surgical Implant Company -*

SANTA BARBARA, Calif. (April 18, 2007) -- Sientra Inc., a specialty medical device company focused on plastic surgery and aesthetics medicine, today announced the close of an \$85 million Series B financing, one of the largest private funding rounds in the medical device sector. Sientra also announced that it has acquired the assets of Silimed Inc., a leading developer of plastic surgery implants for both cosmetic and reconstructive surgery.

Founded by Hani Zeini, a veteran in the aesthetics market whose most recent experience includes leading INAMED Aesthetics prior to the sale of INAMED Corporation to Allergan, and Robert Adelman, MD, a Private Equity Partner at OrbiMed Advisors in New York, Sientra will develop and market products aimed at the fast-growing aesthetics and plastic surgery markets.

OrbiMed Advisors LLC led the transaction, which was financially co-led by Clarus Ventures, and included Goldman Sachs and TIAA-CREF. Sientra plans to use the proceeds to finance the Silimed acquisition, scale-up its commercial organization, advance product development and fund ongoing operational expenses.

“Our vision is to become a leading player in the expanding aesthetics and plastic surgery markets and these two transactions will accelerate our timeline to achieve our goals,” said

Mr. Zeini, who leads the company as its Chief Executive Officer. “We’ve assembled a stellar group of investors whose track record in life sciences and medical device investments will provide us with real strategic advantages. With a world-class management team and such strong backing we intend to execute rapidly on our plans.”

“Americans underwent 11 million cosmetic plastic surgery procedures in 2006 and the market continues to grow offering tremendous opportunity to companies with innovative products,” OrbiMed’s Robert Adelman, MD said. “Hani Zeini and his team bring an impressive track record of performance to Sientra and we expect them to be able to quickly realize the company’s sizable market opportunities.”

“As a result of this near-record financing and acquisition of a proven product portfolio, Sientra has emerged as a competitive force in the plastic surgery and aesthetics markets. We are pleased to be working with Hani and his team as they take the company to the next level of growth,” said Nick Simon, Managing Director, Clarus Ventures.

### **About Sientra, Inc**

Headquartered in Santa Barbara CA, Sientra is a medical device company focused on developing and marketing a broad portfolio of products aimed at the fast growing plastic surgery and aesthetics market.

### **About OrbiMed**

Founded in 1989, OrbiMed is the world’s largest fully dedicated healthcare asset management firm, with approximately \$6 billion in assets under management. Since inception of its private equity investment activities, OrbiMed has successfully made investments in over 70 companies across a wide range of therapeutic categories and stages of development. OrbiMed’s investment team includes over 20 experienced professionals with backgrounds in science, medicine, finance and law. Our professionals work together using a collaborative, team oriented approach which has earned OrbiMed a reputation as the capital provider of choice for life sciences companies of all stages. For more information visit [www.orbimed.com](http://www.orbimed.com).

## **About Clarus Ventures**

Clarus Ventures is a life sciences venture capital firm founded by a team of accomplished investment professionals with extensive and complementary industry backgrounds which have enabled them to establish a long history of success in creating value. Their deep relationships with world thought leaders and decision makers allow this team to identify unique investment opportunities and shepherd them to maturity. Clarus augments its core expertise of investing in biopharmaceuticals and medical technology companies with the deep and diverse expertise of the team in research and development, commercialization, business development and operations management at the global level. Clarus is headquartered in Cambridge, MA and has offices in South San Francisco, CA.

# # #